Last reviewed · How we verify
Azithromycin to pregnant women
Azithromycin to pregnant women is a Small molecule drug developed by University of Maryland, Baltimore. It is currently FDA-approved.
Azithromycin, marketed by the University of Maryland, Baltimore, is an established antibiotic with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad usage, positioning it as a reliable option in the antibiotic market. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Azithromycin to pregnant women |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improving Cognition and Gestational Duration With Targeted Nutrition (NA)
- Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (PHASE4)
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol] (NA)
- Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth (PHASE3)
- International Milk Composition (IMiC) Consortium
- Genital CT Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Pilot RCT (NA)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin to pregnant women CI brief — competitive landscape report
- Azithromycin to pregnant women updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI